Additionally, for patients with other urinary diseases, the Vimentin/POU4F2 combined methylation panel exhibited high specificity (96.30%), particularly for benign urinary diseases, where the specificity reached 100.00% (Fig. 4 and Tab. This evidence concerns the gene POU4F2 and urinary system disorder.